Selective modulation of amyloid-β peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Aβ levels

Journal of Neurochemistry

Volumn 111, Issue 3, 2009, Pages 683-695

  Abdul Hay, Samer O ^a   Edirisinghe, Praneeth ^a   Thatcher, Gregory R J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Alzheimer's disease; Amyloid; Non steroidal anti inflammatory drug; Protease

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-37]; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; FENOFIBRATE; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG SELECTIVITY; GENETIC TRANSFECTION; IMMUNOPRECIPITATION; MASS SPECTROMETRY; MUTANT; NEUROBLASTOMA CELL; NEUROMODULATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; WILD TYPE;

AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CELL LINE, TUMOR; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLURBIPROFEN; HUMANS; IMMUNOPRECIPITATION; MICE; NEUROBLASTOMA; PEPTIDE FRAGMENTS; PROCETOFEN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRANSFECTION;

EID: 70349913875     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.06355.x     Document Type: Article

References (72)

1. Akiyama H., Barger S., Barnum S. et al. (2000) Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383 421.
2. Akiyama H., Kondo H., Ikeda K., Kato M. McGeer P. L. (2001) Immunohistochemical localization of neprilysin in the human cerebral cortex: inverse association with vulnerability to amyloid beta-protein (Abeta) deposition. Brain Res. 902, 277 281.
3. Bateman R. J., Munsell L. Y., Morris J. C., Swarm R., Yarasheski K. E. Holtzman D. M. (2006) Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12, 856 861.
4. Beher D., Clarke E. E., Wrigley J. D., Martin A. C., Nadin A., Churcher I. Shearman M. S. (2004) Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J. Biol. Chem. 279, 43419 43426.
5. Bertram L. Tanzi R. E. (2004) The current status of Alzheimer's disease genetics: what do we tell the patients? Pharmacol. Res. 50, 385 396.
6. Blennow K., de Leon M. J. Zetterberg H. (2006) Alzheimer's disease. Lancet 368, 387 403.
7. Bolla M., Almirante N. Benedini F. (2005) Therapeutic potential of nitrate esters of commonly used drugs. Curr. Top. Med. Chem. 5, 707 720.
8. Brouwers N., Sleegers K. Van Broeckhoven C. (2008) Molecular genetics of Alzheimer's disease: an update. Ann. Med. 40, 562 583.
9. Cacabelos R. (2008) Pharmacogenomics and therapeutic prospects in dementia. Eur. Arch. Psychiatry Clin. Neurosci. 258 (Suppl. 1 28 47.
10. Camacho I. E., Serneels L., Spittaels K., Merchiers P., Dominguez D. De Strooper B. (2004) Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J. Neurosci. 24, 10908 10917.
11. Caselli R. J., Beach T. G., Yaari R. Reiman E. M. (2006) Alzheimer's disease a century later. J. Clin. Psychiatry 67, 1784 1800.
12. Cook D. G., Leverenz J. B., McMillan P. J. et al. (2003) Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am. J. Pathol. 162, 313 319.
13. Czirr E., Cottrell B. A., Leuchtenberger S. et al. (2008) Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase. J. Biol. Chem. 283, 17049 17054.
14. Desai A. K. Grossberg G. T. (2005) Diagnosis and treatment of Alzheimer's disease. Neurology 64, S34 S39.
15. Du P., Wood K. M., Rosner M. H., Cunningham D., Tate B. Geoghegan K. F. (2007) Dominance of amyloid precursor protein sequence over host cell secretases in determining beta-amyloid profiles studies of interspecies variation and drug action by internally standardized immunoprecipitation/mass spectrometry. J.Pharmacol. Exp. Ther. 320, 1144 1152.
16. Eckman C. B. Eckman E. A. (2007) An update on the amyloid hypothesis Neurol. Clin. 25, 669 682, vi.
17. Eriksen J. L., Sagi S. A., Smith T. E. et al. (2003) NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 112, 440 449.
18. Filippatos T. Milionis H. J. (2008) Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin. Investig. Drugs 17, 1599 1614.
19. Findeis M. A. (2007) The role of amyloid beta peptide 42 in Alzheimer's disease. Pharmacol. Ther. 116, 266 286.
20. Gasparini L., Rusconi L., Xu H., del Soldato P. Ongini E. (2004) Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures. J. Neurochem. 88, 337 348.
21. Glabe C. G. (2006) Common mechanisms of amyloid oligomer pathogenesis in degenerative disease. Neurobiol. Aging 27, 570 575.
22. Griffin W. S., Sheng J. G., Royston M. C., Gentleman S. M., McKenzie J. E., Graham D. I., Roberts G. W. Mrak R. E. (1998) Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. Brain Pathol. 8, 65 72.
23. Hardy J. Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353 356.
24. Heneka M. T., Sastre M., Dumitrescu-Ozimek L. et al. (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128, 1442 1453.
25. Hoenicka J. (2006) Genes in Alzheimer's disease. Rev. Neurol. 42, 302 305.
26. Imbimbo B. P., Del Giudice E., Cenacchi V. et al. (2007a) In vitro and in vivo profiling of CHF5022 and CHF5074 Two beta-amyloid 1-42 lowering agents. Pharmacol. Res. 55, 318 328.
27. Imbimbo B. P., Del Giudice E., Colavito D. et al. (2007b) 1-(3′,4′-Dichloro-2-fluoro[1,1′-biphenyl]-4-yl) -cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J. Pharmacol. Exp. Ther. 323, 822 830.
28. Imbimbo B., Hutter-Paier B., Villetti G., Facchinetti F., Cenacchi V., Volta R., Lanzillotta A., Pizzi M. Windisch M. (2009) CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. Br. J. Pharmacol. 156, 982 993.
29. Jiang Q., Lee C. Y., Mandrekar S. et al. (2008) ApoE promotes the proteolytic degradation of Abeta. Neuron 58, 681 693.
30. Kametani F., Nakamura Y., Tanaka K., Hashimoto R. Takeda M. (1999) Semiquantitative analysis of amyloid beta peptides using a combination of immunoprecipitation and matrix-assisted laser desorption ionization/time-of- flight-mass spectrometry. Anal. Biochem. 275, 262 265.
31. Kim J., Onstead L., Randle S., Price R., Smithson L., Zwizinski C., Dickson D. W., Golde T. McGowan E. (2007) Abeta40 inhibits amyloid deposition in vivo. J. Neurosci. 27, 627 633.
32. Kojo H., Fukagawa M., Tajima K., Suzuki A., Fujimura T., Aramori I., Hayashi K. Nishimura S. (2003) Evaluation of human peroxisome proliferator-activated receptor (PPAR) subtype selectivity of a variety of anti-inflammatory drugs based on a novel assay for PPAR delta(beta). J. Pharmacol. Sci. 93, 347 355.
33. Kukar T., Murphy M. P., Eriksen J. L. et al. (2005) Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat. Med. 11, 545 550.
34. Kukar T., Prescott S., Eriksen J. L., Holloway V., Murphy M. P., Koo E. H., Golde T. E. Nicolle M. M. (2007) Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci 8, 54.
35. Kukar T. L., Ladd T. B., Bann M. A. et al. (2008) Substrate-targeting gamma-secretase modulators. Nature 453, 925 929.
36. Lee V. M. Trojanowski J. Q. (1992) The disordered neuronal cytoskeleton in Alzheimer's disease. Curr. Opin. Neurobiol. 2, 653 656.
37. Lehmann J. M., Lenhard J. M., Oliver B. B., Ringold G. M. Kliewer S. A. (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272, 3406 3410.
38. Mackenzie I. R. Munoz D. G. (1998) Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 50, 986 990.
39. McGeer P. L. McGeer E. G. (1996) Anti-inflammatory drugs in the fight against Alzheimer's disease. Ann. NY Acad. Sci. 777, 213 220.
40. McGowan E., Pickford F., Kim J. et al. (2005) Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47, 191 199.
41. Miners J. S., Baig S., Palmer J., Palmer L. E., Kehoe P. G. Love S. (2008) Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol. 18, 240 252.
42. Morgan D., Gordon M. N., Tan J., Wilcock D. Rojiani A. M. (2005) Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J. Neuropathol. Exp. Neurol. 64, 743 753.
43. Morihara T., Chu T., Ubeda O., Beech W. Cole G. M. (2002) Selective inhibition of Abeta42 production by NSAID R-enantiomers. J. Neurochem. 83, 1009 1012.
44. Nalivaeva N. N., Fisk L. R., Belyaev N. D. Turner A. J. (2008) Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr. Alzheimer Res. 5, 212 224.
45. Narlawar R., Perez Revuelta B. I., Haass C., Steiner H., Schmidt B. Baumann K. (2006) Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators. J. Med. Chem. 49, 7588 7591.
46. Page R. M., Baumann K., Tomioka M. et al. (2008) Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. J. Biol. Chem. 283, 677 683.
47. Pang L., Nie M., Corbett L. Knox A. J. (2003) Cyclooxygenase-2 expression by nonsteroidal anti-inflammatory drugs in human airway smooth muscle cells: role of peroxisome proliferator-activated receptors. J. Immunol. 170, 1043 1051.
48. Peretto I., Radaelli S., Parini C. et al. (2005) Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. J. Med. Chem. 48, 5705 5720.
49. Qiu W. Q., Ye Z., Kholodenko D., Seubert P. Selkoe D. J. (1997) Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J. Biol. Chem. 272, 6641 6646.
50. Qiu W. Q., Walsh D. M., Ye Z. et al. (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 273, 32730 32738.
51. Reinhard C., Hebert S. S. De Strooper B. (2005) The amyloid-beta precursor protein: integrating structure with biological function. EMBO J. 24, 3996 4006.
52. Rich J. B., Rasmusson D. X., Folstein M. F., Carson K. A., Kawas C. Brandt J. (1995) Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45, 51 55.
53. Sagare A., Deane R., Bell R. D. et al. (2007) Clearance of amyloid-beta by circulating lipoprotein receptors. Nat. Med. 13, 1029 1031.
54. Sastre M., Dewachter I., Landreth G. E., Willson T. M., Klockgether T., van Leuven F. Heneka M. T. (2003) Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J. Neurosci. 23, 9796 9804.
55. Sastre M., Dewachter I., Rossner S. et al. (2006) Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl Acad. Sci. USA 103, 443 448.
56. Scott Kim W., Chan S. L., Hill A. F., Guillemin G. J. Garner B. (2009) Impact of 27-hydroxycholesterol on amyloid-beta peptide production and ATP-binding cassette transporter expression in primary human neurons. J. Alzheimers Dis. 16, 121 131.
57. Stewart W. F., Kawas C., Corrada M. Metter E. J. (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626 632.
58. Stock N., Munoz B., Wrigley J. D. et al. (2006) The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg. Med. Chem. Lett. 16, 2219 2223.
59. Streel B., Hubert P. Ceccato A. (2000) Determination of fenofibric acid in human plasma using automated solid-phase extraction coupled to liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 742, 391 400.
60. Takahashi Y., Hayashi I., Tominari Y. et al. (2003) Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J. Biol. Chem. 278, 18664 18670.
61. Thomas J., Bramlett K. S., Montrose C. et al. (2003) A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha) versus liver X receptor. J. Biol. Chem. 278, 2403 2410.
62. in t' Veld B. A., Ruitenberg A., Hofman A., Launer L. J., van Duijn C. M., Stijnen T., Breteler M. M. Stricker B. H. (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. 345, 1515 1521.
63. Wang Y. J., Zhou H. D. Zhou X. F. (2006) Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. Drug Discov. Today 11, 931 938.
64. Weggen S., Eriksen J. L., Das P. et al. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212 216.
65. Wilcock G. K., Black S. E., Hendrix S. B., Zavitz K. H., Swabb E. A. Laughlin M. A. (2008) Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 7, 483 493.
66. Willson T. M., Brown P. J., Sternbach D. D. Henke B. R. (2000) The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43, 527 550.
67. Wiltfang J., Esselmann H., Bibl M. et al. (2002) Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J. Neurochem. 81, 481 496.
68. Wurch T., Junquero D., Delhon A. Pauwels J. (2002) Pharmacological analysis of wild-type alpha, gamma and delta subtypes of the human peroxisome proliferator-activated receptor. Naunyn Schmiedebergs Arch. Pharmacol. 365, 133 140.
69. Yasojima K., Akiyama H., McGeer E. G. McGeer P. L. (2001) Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci. Lett. 297, 97 100.
70. Zhang L., Song L., Terracina G., Liu Y., Pramanik B. Parker E. (2001) Biochemical characterization of the gamma-secretase activity that produces beta-amyloid peptides. Biochemistry 40, 5049 5055.
71. Zhao Z., Xiang Z., Haroutunian V., Buxbaum J. D., Stetka B. Pasinetti G. M. (2007) Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol. Aging 28, 824 830.
72. Zhou Y., Su Y., Li B. et al. (2003) Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 302, 1215 1217.